{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:07:15Z","timestamp":1778760435044,"version":"3.51.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07014-z","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T08:20:30Z","timestamp":1776673230000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HLA-matched versus haploidentical donor transplantation with post-transplant cyclophosphamide: a study on behalf of the donor\/source working group of the Japanese society for transplantation and cellular therapy"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3337-1599","authenticated-orcid":false,"given":"Yosuke","family":"Nakaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4203-990X","authenticated-orcid":false,"given":"Hirohisa","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3852-5075","authenticated-orcid":false,"given":"Junichi","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-3633","authenticated-orcid":false,"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9925-2093","authenticated-orcid":false,"given":"Yuta","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2630-493X","authenticated-orcid":false,"given":"Tetsuya","family":"Eto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-4307","authenticated-orcid":false,"given":"Naoki","family":"Kurita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0472-6680","authenticated-orcid":false,"given":"Nobuhiro","family":"Hiramoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4795-121X","authenticated-orcid":false,"given":"Koji","family":"Nagafuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-244X","authenticated-orcid":false,"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0148-644X","authenticated-orcid":false,"given":"Noboru","family":"Asada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0131-2570","authenticated-orcid":false,"given":"Takashi","family":"Akasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6425-1720","authenticated-orcid":false,"given":"Yasuo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiko","family":"Kamimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3864-0823","authenticated-orcid":false,"given":"Makoto","family":"Onizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5812-9315","authenticated-orcid":false,"given":"Hideki","family":"Nakasone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"7014_CR1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ et al (2008) HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl 14:641\u2013650","journal-title":"Biol Blood Marrow Transpl"},{"key":"7014_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3324\/haematol.2016.151779","volume":"102","author":"A Ruggeri","year":"2017","unstructured":"Ruggeri A, Sun Y, Labopin M et al (2017) Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant. Haematologica 102:401\u2013410","journal-title":"Haematologica"},{"key":"7014_CR3","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/ajh.25087","volume":"93","author":"Z Li","year":"2018","unstructured":"Li Z, Labopin M, Ciceri F et al (2018) Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study. Am J Hematol 93:769\u2013777","journal-title":"Am J Hematol"},{"key":"7014_CR4","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.3324\/haematol.2020.247296","volume":"106","author":"A Nagler","year":"2021","unstructured":"Nagler A, Kanate AS, Labopin M et al (2021) Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia. Haematologica 106:1591\u20131598","journal-title":"Haematologica"},{"key":"7014_CR5","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1002\/cncr.35365","volume":"130","author":"AH Bazarbachi","year":"2024","unstructured":"Bazarbachi AH, Labopin M, Raiola AM et al (2024) Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft\u2010versus\u2010host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. Cancer 130:3123\u20133136","journal-title":"Cancer"},{"key":"7014_CR6","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","volume":"115","author":"L Luznik","year":"2010","unstructured":"Luznik L, Bolanos-Meade J, Zahurak M et al (2010) High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 115:3224\u20133230","journal-title":"Blood"},{"key":"7014_CR7","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1200\/JCO.2013.54.0625","volume":"32","author":"CG Kanakry","year":"2014","unstructured":"Kanakry CG, O\u2019Donnell PV, Furlong T et al (2014) Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol 32:3497\u20133505","journal-title":"J Clin Oncol"},{"key":"7014_CR8","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1182\/blood-2014-07-587477","volume":"124","author":"CG Kanakry","year":"2014","unstructured":"Kanakry CG, Tsai HL, Bolanos-Meade J et al (2014) Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood 124:3817\u20133827","journal-title":"Blood"},{"key":"7014_CR9","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.bbmt.2015.01.020","volume":"21","author":"KF Bradstock","year":"2015","unstructured":"Bradstock KF, Bilmon I, Kwan J et al (2015) Single-Agent High-Dose Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Human Leukocyte Antigen-Matched Reduced-Intensity Peripheral Blood Stem Cell Transplantation Results in an Unacceptably High Rate of Severe Acute Graft-versus-Host Disease. Biol Blood Marrow Transpl 21:941\u2013944","journal-title":"Biol Blood Marrow Transpl"},{"key":"7014_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ejh.12541","volume":"96","author":"U Holtick","year":"2016","unstructured":"Holtick U, Chemnitz JM, Shimabukuro-Vornhagen A et al (2016) OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Eur J Haematol 96:27\u201335","journal-title":"Eur J Haematol"},{"key":"7014_CR11","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1182\/blood-2015-10-672071","volume":"127","author":"M Mielcarek","year":"2016","unstructured":"Mielcarek M, Furlong T, O\u2019Donnell PV et al (2016) Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood 127:1502\u20131508","journal-title":"Blood"},{"key":"7014_CR12","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1182\/blood-2016-09-737825","volume":"129","author":"CG Kanakry","year":"2017","unstructured":"Kanakry CG, Bolanos-Meade J, Kasamon YL et al (2017) Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood 129:1389\u20131393","journal-title":"Blood"},{"key":"7014_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-018-0586-4","volume":"11","author":"A Ruggeri","year":"2018","unstructured":"Ruggeri A, Labopin M, Bacigalupo A et al (2018) Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. J Hematol Oncol 11:40","journal-title":"J Hematol Oncol"},{"key":"7014_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12185-021-03228-1","volume":"115","author":"H Nakamae","year":"2022","unstructured":"Nakamae H, Nakane T, Okamura H et al (2022) A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related\/unrelated allogeneic hematopoietic stem cell transplantation. Int J Hematol 115:77\u201386","journal-title":"Int J Hematol"},{"key":"7014_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41409-023-02162-6","volume":"59","author":"J Sugita","year":"2024","unstructured":"Sugita J, Kuroha T, Ishikawa J et al (2024) Posttransplant cyclophosphamide in unrelated and related peripheral blood stem cell transplantation from HLA-matched and 1 allele mismatched donor. Bone Marrow Transpl 59:344\u2013349","journal-title":"Bone Marrow Transpl"},{"key":"7014_CR16","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","volume":"6","author":"AEC Broers","year":"2022","unstructured":"Broers AEC, de Jong CN, Bakunina K et al (2022) Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv 6:3378\u20133385","journal-title":"Blood Adv"},{"key":"7014_CR17","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bolanos-Meade","year":"2023","unstructured":"Bolanos-Meade J, Hamadani M, Wu J et al (2023) Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. N Engl J Med 388:2338\u20132348","journal-title":"N Engl J Med"},{"key":"7014_CR18","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/bmt.2016.217","volume":"51","author":"A Rashidi","year":"2016","unstructured":"Rashidi A, Slade M, DiPersio JF, Westervelt P, Vij R, Romee R (2016) Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML. Bone Marrow Transpl 51:1561\u20131564","journal-title":"Bone Marrow Transpl"},{"key":"7014_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1182\/blood.2021011281","volume":"138","author":"M Gooptu","year":"2021","unstructured":"Gooptu M, Romee R, St Martin A et al (2021) HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood 138:273\u2013282","journal-title":"Blood"},{"key":"7014_CR20","first-page":"184","volume":"29","author":"A Mussetti","year":"2023","unstructured":"Mussetti A, Kanate AS, Wang T et al (2023) Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas. Transpl Cell Ther 29:184 e181-184 e189","journal-title":"Transpl Cell Ther"},{"key":"7014_CR21","first-page":"210","volume":"30","author":"J Montoro","year":"2024","unstructured":"Montoro J, Boumendil A, Finel H et al (2024) Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Transpl Cell Ther 30:210 e211-210 e214","journal-title":"Transpl Cell Ther"},{"key":"7014_CR22","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1038\/s41409-020-0921-6","volume":"55","author":"J Montoro","year":"2020","unstructured":"Montoro J, Pinana JL, Hernandez-Boluda JC et al (2020) Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. Bone Marrow Transpl 55:2147\u20132159","journal-title":"Bone Marrow Transpl"},{"key":"7014_CR23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-020-00882-6","volume":"13","author":"J Sanz","year":"2020","unstructured":"Sanz J, Galimard JE, Labopin M et al (2020) Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. J Hematol Oncol 13:46","journal-title":"J Hematol Oncol"},{"key":"7014_CR24","first-page":"204","volume":"28","author":"R Bailen","year":"2022","unstructured":"Bailen R, Pascual-Cascon MJ, Guerreiro M et al (2022) Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC. Transpl Cell Ther 28:204 e201-204 e210","journal-title":"Transpl Cell Ther"},{"key":"7014_CR25","first-page":"395","volume":"28","author":"RS Mehta","year":"2022","unstructured":"Mehta RS, Saliba RM, Ghanem S et al (2022) Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transpl Cell Ther 28:395 e391-395 e311","journal-title":"Transpl Cell Ther"},{"key":"7014_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.bbmt.2004.12.327","volume":"11","author":"M Mielcarek","year":"2005","unstructured":"Mielcarek M, Gooley T, Martin PJ et al (2005) Effects of race on survival after stem cell transplantation. Biol Blood Marrow Transpl 11:231\u2013239","journal-title":"Biol Blood Marrow Transpl"},{"key":"7014_CR27","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2004-06-2385","volume":"105","author":"H Oh","year":"2005","unstructured":"Oh H, Loberiza FR Jr., Zhang MJ et al (2005) Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood 105:1408\u20131416","journal-title":"Blood"},{"key":"7014_CR28","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.bbmt.2013.05.020","volume":"19","author":"Y Morishima","year":"2013","unstructured":"Morishima Y, Kawase T, Malkki M et al (2013) Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 19:1197\u20131203","journal-title":"Biol Blood Marrow Transpl"},{"key":"7014_CR29","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.bbmt.2015.12.027","volume":"22","author":"J Kanda","year":"2016","unstructured":"Kanda J, Brazauskas R, Hu ZH et al (2016) Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations. Biol Blood Marrow Transpl 22:744\u2013751","journal-title":"Biol Blood Marrow Transpl"},{"key":"7014_CR30","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1182\/bloodadvances.2019000386","volume":"3","author":"Y Inamoto","year":"2019","unstructured":"Inamoto Y, White J, Ito R et al (2019) Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients. Blood Adv 3:2764\u20132777","journal-title":"Blood Adv"},{"key":"7014_CR31","doi-asserted-by":"crossref","unstructured":"Morishima Y, Morishima S, Stevenson P et al (2022) Race and Survival in Unrelated Hematopoietic Cell Transplantation. Transplant Cell Ther 28:357.e351-357.e356","DOI":"10.1016\/j.jtct.2022.03.026"},{"key":"7014_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","volume":"103","author":"Y Atsuta","year":"2016","unstructured":"Atsuta Y (2016) Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol 103:3\u201310","journal-title":"Int J Hematol"},{"key":"7014_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12185-015-1907-9","volume":"103","author":"J Kanda","year":"2016","unstructured":"Kanda J (2016) Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation. Int J Hematol 103:11\u201319","journal-title":"Int J Hematol"},{"key":"7014_CR34","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","volume":"125","author":"SG Holtan","year":"2015","unstructured":"Holtan SG, DeFor TE, Lazaryan A et al (2015) Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood 125:1333\u20131338","journal-title":"Blood"},{"key":"7014_CR35","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","volume":"129","author":"T Yoshizato","year":"2017","unstructured":"Yoshizato T, Nannya Y, Atsuta Y et al (2017) Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood 129:2347\u20132358","journal-title":"Blood"},{"key":"7014_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41409-020-00996-y","volume":"56","author":"H Muranushi","year":"2021","unstructured":"Muranushi H, Shindo T, Hishizawa M et al (2021) GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia\/lymphoma. Bone Marrow Transpl 56:155\u2013166","journal-title":"Bone Marrow Transpl"},{"key":"7014_CR37","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/bjh.19835","volume":"206","author":"M Yoshimitsu","year":"2025","unstructured":"Yoshimitsu M, Tanaka T, Nakano N et al (2025) Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia\/lymphoma. Br J Haematol 206:235\u2013249","journal-title":"Br J Haematol"},{"key":"7014_CR38","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1056\/NEJM200106143442402","volume":"344","author":"MJ Laughlin","year":"2001","unstructured":"Laughlin MJ, Barker J, Bambach B et al (2001) Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 344:1815\u20131822","journal-title":"N Engl J Med"},{"key":"7014_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S et al (2016) International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transpl 22:4\u201310","journal-title":"Biol Blood Marrow Transpl"},{"key":"7014_CR40","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M et al (2015) National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl 21:389\u2013401e381","journal-title":"Biol Blood Marrow Transpl"},{"key":"7014_CR41","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D et al (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl 15:1628\u20131633","journal-title":"Biol Blood Marrow Transpl"},{"key":"7014_CR42","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D et al (2009) Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transpl 15:367\u2013369","journal-title":"Biol Blood Marrow Transpl"},{"key":"7014_CR43","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"7014_CR44","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912\u20132919","journal-title":"Blood"},{"key":"7014_CR45","doi-asserted-by":"publisher","first-page":"E447","DOI":"10.1002\/ajh.26722","volume":"97","author":"T Konuma","year":"2022","unstructured":"Konuma T, Shimomura Y, Ishiyama K et al (2022) Haploidentical transplantation with post-transplant cyclophosphamide versus single cord blood transplantation for myelodysplastic syndrome: A retrospective study from the Adult Myelodysplastic Syndrome Working Group of the Japanese Society for Transplantation and Cellular Therapy (JSTCT). Am J Hematol 97:E447\u2013E450","journal-title":"Am J Hematol"},{"key":"7014_CR46","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/ajh.26446","volume":"97","author":"F Wada","year":"2022","unstructured":"Wada F, Watanabe M, Konuma T et al (2022) HLA 1\u20133 antigen-mismatched related peripheral blood stem cells transplantation using low-dose antithymocyte globulin versus unrelated cord blood transplantation. Am J Hematol 97:311\u2013321","journal-title":"Am J Hematol"},{"key":"7014_CR47","first-page":"316","volume":"30","author":"Y Nakaya","year":"2024","unstructured":"Nakaya Y, Koh H, Konuma T et al (2024) HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus HLA-Matched Unrelated Donor Transplantation for Myelodysplastic Syndrome. Transpl Cell Ther 30:316 e311-316 e312","journal-title":"Transpl Cell Ther"},{"key":"7014_CR48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12874-017-0338-0","volume":"17","author":"TL Nguyen","year":"2017","unstructured":"Nguyen TL, Collins GS, Spence J et al (2017) Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance. BMC Med Res Methodol 17:78","journal-title":"BMC Med Res Methodol"},{"key":"7014_CR49","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl 48:452\u2013458","journal-title":"Bone Marrow Transpl"},{"key":"7014_CR50","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1182\/bloodadvances.2022007741","volume":"6","author":"A Ambinder","year":"2022","unstructured":"Ambinder A, Jain T, Tsai HL, Horowitz MM, Jones RJ, Varadhan R (2022) HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age. Blood Adv 6:4335\u20134346","journal-title":"Blood Adv"},{"key":"7014_CR51","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-021-01094-2","volume":"14","author":"J Sanz","year":"2021","unstructured":"Sanz J, Galimard JE, Labopin M et al (2021) Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT. J Hematol Oncol 14:84","journal-title":"J Hematol Oncol"},{"key":"7014_CR52","first-page":"233","volume":"30","author":"JS Little","year":"2024","unstructured":"Little JS, Dulery R, Shapiro RM et al (2024) Opportunistic Infections in Patients Receiving Post-Transplantation Cyclophosphamide: Impact of Haploidentical versus Unrelated Donor Allograft. Transpl Cell Ther 30:233 e231-233 e214","journal-title":"Transpl Cell Ther"},{"key":"7014_CR53","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41409-023-02010-7","volume":"58","author":"JD Marra","year":"2023","unstructured":"Marra JD, Galli E, Giammarco S et al (2023) Effect of HLA mismatch on post-transplant infections in allogeneic hematopoietic stem cell transplantation with PTCy-based GvHD prophylaxis. Bone Marrow Transpl 58:1042\u20131044","journal-title":"Bone Marrow Transpl"},{"key":"7014_CR54","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jiac.2016.05.006","volume":"22","author":"U Sahin","year":"2016","unstructured":"Sahin U, Toprak SK, Atilla PA, Atilla E, Demirer T (2016) An overview of infectious complications after allogeneic hematopoietic stem cell transplantation. J Infect Chemother 22:505\u2013514","journal-title":"J Infect Chemother"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07014-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07014-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07014-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:07:43Z","timestamp":1778756863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07014-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":54,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["7014"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07014-z","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Ethics Committee of Osaka Metropolitan University Graduate School of Medicine in accordance with the Declaration of Helsinki (approval number: 2024-057).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients included in this study provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Hideki Nakasone received subsidies from JCR Pharmaceuticals, Kyowa Kirin, Taiho Pharmaceutical, Santen Pharmaceutical, and TERUMO, and honoraria from MSD, Otsuka Pharmaceutical, Pfizer, Novartis, Takeda Pharmaceutical, Janssen Pharmaceutical, Chugai Pharmaceutical, Sanofi, Meiji Seika Pharma, Bristol Myers Squibb, and Asahi Kasei Pharma. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"255"}}